You know your questions – let us bring you the right real-world answers
Achieving launch excellence in the pharmaceutical industry is increasingly rare and complex. Based on well-defined, objective criteria, a small fraction of launches achieves launch excellence. The key challenges to achieving launch excellence are healthcare system capacity gaps, timely and compelling evidence and stakeholder engagement. At a recent expert panel, industry leaders shared candid insights on how medical affairs teams are driving success—and what challenges remain. Setting the stage for this discussion, David Kelaher, Sr Director, Medical Affairs, IQVIA emphasized the need for early and proactive involvement of medical affairs, robust evidence planning, and cross-functional collaboration to overcome these barriers and drive successful launches.
Only 11% of specialty launches and 4% of primary care launches achieve true excellence. The reasons? Healthcare system capacity gaps, evolving stakeholder needs, and the growing demand for timely, compelling evidence.
Key Pillars for Launch Success:
Dr. Ehab Saad, Oncology Medical Head for Novartis Gulf, addressed the perennial question of how launch excellence is measured: “Sales outcomes will always be the best indicator for a successful launch. However, medical affairs can drive lead indicators that can predict and sustain those results. As medical affairs, impact can be assessed in both qualitative and quantitative metrics—such as scientific engagement quality, evidence generation and dissemination, and adoption of new modes of action—that can give you the right direction and confidence for an excellent launch.”
He emphasized, “Healthcare system readiness is crucial. Engaging earlier with multiple stakeholders in the patient journey is very important and critical. Competing for the time of our physicians is becoming more and more challenging, so innovation in how we deliver the right messages is key.”
Dr. Walaa AlBenayan, Director of Medical Affairs at Biogen GCC, highlighted the evolving role of medical affairs in rare diseases: “We in medical affairs play an important role in translating clinical outcomes and real-world evidence into value frameworks. Generating local data and local real-world evidence creates more value for regulators and payers.”
She added, “Medical affairs is the scientific backbone. We provide the insights collected from pre-launch activities and help other functions like market access and regulatory in their negotiations and submissions. Our evidence and insights are the backbone to allow other functions to secure early and sustainable access to innovations.”
David Kelaher also spoke about broadening engagement: “Because of the complexity of patient journeys, we need to work with broader sets of stakeholders—patient advocacy groups, digital opinion leaders, and allied healthcare professionals. Our educational and evidence initiatives must be fit for purpose and have an impact in the community, not just among KOLs.”
The panel’s perspectives make it clear: medical affairs is no longer a supporting function—it’s a strategic driver of launch excellence. By engaging early, generating relevant evidence, collaborating across functions, and amplifying their voice, medical affairs professionals can unlock the full potential of their organizations and deliver meaningful impact for patients, providers, and payers.
Missed the webinar? Watch the on-demand version here.
You know your questions – let us bring you the right real-world answers